Alkermes Inc. lost two development partnerships last week, but the company said that its drug delivery technology has addressed technical questions and achieved proof of principle, making the terminations a refocusing of resources rather than a negative comment on company progress.

ALKS (Cambridge, Mass.) last week announced the mutual termination of its partnerships covering ProLease sustained-release formulations of an R.W. Johnson Pharmaceutical Research Institute product candidate to treat hormone-mediated disorders and covering ProLease formulations of Schering-Plough Corp.'s Intron A interferon alfa-2b.